These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 17065627)

  • 21. Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae.
    Walsh F; Carnegy F; Willcock J; Amyes S
    J Antimicrob Chemother; 2004 May; 53(5):793-6. PubMed ID: 15056640
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genotypes of macrolide-resistant pneumococci from children in southwestern Japan: raised incidence of strains that have both erm(B) and mef(A) with serotype 6B clones.
    Ikenaga M; Kosowska-Shick K; Gotoh K; Hidaka H; Koga H; Masunaga K; Nagai K; Tsumura N; Appelbaum PC; Matsuishi T
    Diagn Microbiol Infect Dis; 2008 Sep; 62(1):16-22. PubMed ID: 18068325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Macrolide and ketolide resistance with Streptococcus pneumoniae.
    Doern GV
    Med Clin North Am; 2006 Nov; 90(6):1109-24. PubMed ID: 17116439
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-level telithromycin resistance in laboratory-generated mutants of Streptococcus pneumoniae.
    Walsh F; Willcock J; Amyes S
    J Antimicrob Chemother; 2003 Sep; 52(3):345-53. PubMed ID: 12917252
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genotypic characterization of macrolide-resistant strains of Streptococcus pneumoniae isolated in Quebec, Canada, and in vitro activity of ABT-773 and telithromycin.
    Weiss K; Guilbault C; Cortes L; Restieri C; Low DE;
    J Antimicrob Chemother; 2002 Sep; 50(3):403-6. PubMed ID: 12205066
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacodynamic activity of telithromycin against macrolide-susceptible and macrolide-resistant Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrations.
    Zhanel GG; Johanson C; Hisanaga T; Mendoza C; Laing N; Noreddin A; Wierzbowski A; Hoban DJ
    J Antimicrob Chemother; 2004 Dec; 54(6):1072-7. PubMed ID: 15531596
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evolution and molecular characterization of macrolide-resistant Streptococcus pneumoniae in Canada between 1998 and 2008.
    Wierzbowski AK; Karlowsky JA; Adam HJ; Nichol KA; Hoban DJ; Zhanel GG;
    J Antimicrob Chemother; 2014 Jan; 69(1):59-66. PubMed ID: 23970485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Susceptibility of Streptococcus pneumoniae to penicillin, azithromycin and telithromycin (PROTEKT 1999-2003).
    Schito GC; Felmingham D
    Int J Antimicrob Agents; 2005 Dec; 26(6):479-85. PubMed ID: 16289710
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacodynamic profile of telithromycin against macrolide- and fluoroquinolone-resistant Streptococcus pneumoniae in a neutropenic mouse thigh model.
    Tessier PR; Mattoes HM; Dandekar PK; Nightingale CH; Nicolau DP
    Antimicrob Agents Chemother; 2005 Jan; 49(1):188-94. PubMed ID: 15616295
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative activity of telithromycin against macrolide-resistant isolates of Streptococcus pneumoniae: results of two years of the PROTEKT surveillance study.
    Schito GC; Marchese A; Elkharrat D; Farrell DJ;
    J Chemother; 2004 Feb; 16(1):13-22. PubMed ID: 15077994
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activity of telithromycin against multi-drug resistant Streptococcus pneumoniae and molecular characterization of macrolide and tetracycline resistance determinants.
    Cascone C; Mezzatesta ML; Santagati M; Cafiso V; Nicoletti G; Stefani S
    J Chemother; 2005 Oct; 17(5):502-8. PubMed ID: 16323438
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro activity of the investigational ketolide cethromycin against macrolide- and penicillin-resistant Streptococcus pneumoniae: review of the 1998 to 2006 Canadian Respiratory Organism Susceptibility Study (CROSS).
    Wierzbowski AK; Karlowsky JA; Hoban DJ; Zhanel GG
    J Antimicrob Chemother; 2009 Mar; 63(3):620-2. PubMed ID: 19151038
    [No Abstract]   [Full Text] [Related]  

  • 33. Mechanisms of resistance to telithromycin in Streptococcus pneumoniae.
    Hisanaga T; Hoban DJ; Zhanel GG
    J Antimicrob Chemother; 2005 Sep; 56(3):447-50. PubMed ID: 16006449
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Macrolide resistance determinants in erythromycin-resistant Streptococcus pneumoniae in Turkey.
    Gulay Z; Ozbek OA; Bicmen M; Gur D
    Jpn J Infect Dis; 2008 Nov; 61(6):490-3. PubMed ID: 19050364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibacterial susceptibility among Streptococcus pneumoniae isolated from paediatric and adult patients as part of the PROTEKT US study in 2001-2002.
    Brown SD; Farrell DJ
    J Antimicrob Chemother; 2004 Aug; 54 Suppl 1():i23-9. PubMed ID: 15265833
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Macrolide resistance mechanisms among Streptococcus pneumoniae isolated over 6 years of Canadian Respiratory Organism Susceptibility Study (CROSS) (1998 2004).
    Wierzbowski AK; Nichol K; Laing N; Hisanaga T; Nikulin A; Karlowsky JA; Hoban DJ; Zhanel GG
    J Antimicrob Chemother; 2007 Oct; 60(4):733-40. PubMed ID: 17673477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence and molecular analysis of macrolide and fluoroquinolone resistance among isolates of Streptococcus pneumoniae collected during the 2000-2001 PROTEKT US Study.
    Brown SD; Farrell DJ; Morrissey I
    J Clin Microbiol; 2004 Nov; 42(11):4980-7. PubMed ID: 15528684
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clonal spread of mef-positive macrolide-resistant Streptococcus pneumoniae isolates causing invasive disease in adults in Germany.
    van der Linden M; Al-Lahham A; Haupts S; Reinert RR
    Antimicrob Agents Chemother; 2007 May; 51(5):1830-4. PubMed ID: 17325214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanisms of macrolide resistance in clinical pneumococcal isolates in a university hospital, Ankara, Turkey.
    Sener B; Köseoglu O; Gür D; Bryskier A
    J Chemother; 2005 Feb; 17(1):31-5. PubMed ID: 15828441
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence, characteristics, and molecular epidemiology of macrolide and fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae at five tertiary-care hospitals in Korea.
    Shin JH; Jung HJ; Kim HR; Jeong J; Jeong SH; Kim S; Lee EY; Lee JN; Chang CL
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2625-7. PubMed ID: 17502407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.